$1.32
+0.02 (+1.54%)
Open$1.33
Previous Close$1.30
Day High$1.35
Day Low$1.24
52W High$8.00
52W Low$1.10
Volume—
Avg Volume58.7K
Market Cap5.19M
P/E Ratio—
EPS$-5.43
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,837.9% upside
Current
$1.32
$1.32
Target
$38.78
$38.78
$26.82
$38.78 avg
$44.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.63M | 2.53M | 2.93M |
| Net Income | 21.2K | 20.0K | 19.6K |
| Profit Margin | 0.8% | 0.8% | 0.7% |
| EBITDA | 30.9K | 30.5K | 37.6K |
| Free Cash Flow | 17.8K | 22.0K | 24.1K |
| Rev Growth | -5.2% | +23.9% | +20.0% |
| Debt/Equity | 0.27 | 0.26 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |